Finance

Traders on the floor of the NYSE, July 12, 2022.
Source: NYSE

Stock futures were little changed in overnight trading on Tuesday as investors awaited a key inflation report that is expected to show a fresh high.

Futures on the Dow Jones Industrial Average edged up 18 points. S&P 500 futures and Nasdaq 100 futures were both flat.

The consumer price index, slated for at 8:30 a.m. ET Wednesday, is expected to climb by 8.8% in June on a year-over-year basis, according to Dow Jones’ survey of economists. That would be even higher than May’s 8.6% reading, which was the biggest increase since 1981.

“The market is anticipating that June will be the new peak,” said Lindsey Bell, Ally’s chief markets and money strategist. “The reading is likely to confirm what the jobs report on Friday told us – that the Fed will stick to their aggressive rate tightening timeline.”

The likely hot reading could prompt the central bank to hike another 75 basis points during this month’s meeting. Last month, the Fed raised its benchmark interest rates three-quarters of a percentage point to a range of 1.5%-1.75% in its most aggressive hike since 1994.

“The Fed’s credibility will be tested in coming months with the release of inflation numbers and corporate earnings,” said Andy Sparks, head of portfolio management research at MSCI. ”The Fed’s recent aggressive actions to bring down inflation also run the risk of overshooting, pushing an economy that had been showing signs of weakness into a full scale recession.”

Meanwhile, investors will monitor second-quarter corporate earnings as major banks are set to report this week. JPMorgan and Morgan Stanley are slated to post results Thursday before the bell. Delta Air Lines reports before the bell Wednesday.

Articles You May Like

Momentum Slows for State Drug Legalization Policies via 2024 State Ballot Initiatives
Mortgage rates may be stabilizing after the election. Here’s what to expect into early 2025
Premium Cigar Taxes by State, 2024
Repealing Head of Household Filing Status: Details and Analysis
Amgen says no concerns around weight loss drug’s bone density data after stock falls